The Diet Advice Nobody Has Tested

Everyone on these drugs is told what to eat: hit a protein target, drink more water, add fiber, take a supplement. A systematic review gathered the 16 randomized trials that could test any of it, covering 7,096 people, and concluded that evidence on the optimal nutritional approach remains limited.^[1] The advice is sensible. It is also, so far, untested.

What the review looked for

The reviewers searched four databases for randomized trials of people taking GLP-1 or dual GIP/GLP-1 drugs alongside dietary or lifestyle guidance, and asked three questions: what happened to gastrointestinal symptoms, to muscle and bone, and to nutritional adequacy.

The row about protein applies to us

The advice is not therefore wrong. Protein requirements during weight loss are reasonably well characterized in general, resistance training and adequate protein have decades of support for preserving muscle while losing weight, and there is no reason to expect these drugs to invert that. What is missing is anyone having tested it in this situation, at these rates of weight loss, with appetite suppressed to the degree these drugs suppress it.

The gap matters most where it is least obvious. Someone eating far less than usual has to fit the same protein into a much smaller total intake, and whether the standard target is achievable or sufficient under those conditions is exactly the question nobody has answered.

Two absences worth naming

No study directly assessed bone health. Not one of sixteen. Weight loss reduces bone density — that is established physiology, covered in bone density and fracture risk — and none of the trials designed to test dietary management alongside these drugs looked at it.

That distinction runs through this whole review. Its findings are mostly about what the literature does not contain, which is a legitimate and useful thing for a systematic review to establish.

The finding that undercuts common advice

Gastrointestinal symptoms increased consistently, were often dose-related, and occurred despite the dietary and lifestyle interventions running in the background of these trials.

The dietary guidance did not prevent the side effects it is usually prescribed to manage.

Eating smaller meals, avoiding fat, going slowly — the standard advice for nausea on these drugs — was being given in these trials, and people were still nauseated at the usual rates. That does not mean it helps nobody. It means the effect is not large enough to show up against the drug’s own dose-related pattern, and that what actually reduces the symptom reliably is going more slowly up the ladder, which now has randomized support in five clicks instead of a quarter milligram.

The one reassuring result

Lean mass was generally preserved, with reductions proportional to overall weight loss — meaning muscle fell in step with body size rather than disproportionately.

That agrees with a different method reaching the same conclusion. An MRI substudy compared muscle loss against what population data predicted for the same weight change and found it no greater than expected, with muscle quality improving more than expected — muscle volume versus muscle function. Two independent approaches, one answer, which is worth more than either alone.